Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mersana Therapeutics, Inc. (MRSN)

7.01   0.12 (1.74%) 02-03 14:33
Open: 6.72 Pre. Close: 6.89
High: 7.125 Low: 6.72
Volume: 673,694 Market Cap: 699(M)

Technical analysis

as of: 2023-02-03 2:18:40 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 8.32     One year: 9.72
Support: Support1: 5.87    Support2: 5.11
Resistance: Resistance1: 7.12    Resistance2: 8.32
Pivot: 6.41
Moving Average: MA(5): 6.75     MA(20): 6.25
MA(100): 6.63     MA(250): 5.49
MACD: MACD(12,26): 0.2     Signal(9): 0
Stochastic oscillator: %K(14,3): 93.6     %D(3): 91.5
RSI: RSI(14): 64.2
52-week: High: 8.33  Low: 2.68
Average Vol(K): 3-Month: 1,081 (K)  10-Days: 787 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MRSN ] has closed below upper band by 12.7%. Bollinger Bands are 8.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7 - 7.03 7.03 - 7.05
Low: 6.56 - 6.59 6.59 - 6.62
Close: 6.84 - 6.89 6.89 - 6.94

Company Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 02 Feb 2023
Mersana Therapeutics to Present at Upcoming Investor Conferences - Benzinga

Wed, 01 Feb 2023
2023-02-01 | NDAQ:MRSN | Press Release | Mersana Therapeutics ... - Stockhouse

Tue, 31 Jan 2023
BlackRock Updates Holdings in Mersana Therapeutics (MRSN) - Nasdaq

Wed, 25 Jan 2023
Mersana Therapeutics Starts Early-Stage Trial of XMT-2056 in Solid Tumors -

Sat, 21 Jan 2023
Mersana Therapeutics (NASDAQ:MRSN) Now Covered by Analysts ... - MarketBeat

Thu, 19 Jan 2023
Noteworthy Thursday Option Activity: MRNA, MRSN, CHPT - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -76 (M)
Shares Float 0 (M)
% Held by Insiders 7.191e+007 (%)
% Held by Institutions 7.058e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.3197e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.43
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 23
Return on Equity (ttm) -47.4
Qtrly Rev. Growth 6.34e+006
Gross Profit (p.s.) 0
Sales Per Share -40.18
EBITDA (p.s.) -5.45331e+007
Qtrly Earnings Growth -1.9087e+008
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -4.91
Price to Sales -0.18
Price to Cash Flow 0

Stock Dividends

Dividend 5.76e+006
Forward Dividend 3.87e+006
Dividend Yield 82109800%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.